Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q4 FY25 results · Jan–Mar 2025
Sun Pharma Advanced Research Company reported revenue from operations of ₹27.19 crore (up 64.2% from Q4 FY24) and net loss of ₹59.77 crore for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 27.19 | 16.56 | +64.2% | 14.91 | +82.4% |
| Other income | 0.00 | 4.40 | −100.0% | 0.19 | −100.0% |
| Total income | 27.19 | 20.96 | +29.7% | 15.10 | +80.1% |
| Profit before tax | (60.67) | (105.41) | Loss narrowed | (79.44) | Loss narrowed |
| Net profit for the period | (59.77) | (105.79) | Loss narrowed | (79.51) | Loss narrowed |
| Attributable to shareholders of the company | (60.16) | — | — | — | — |
| EPS, basic (₹) | (1.84) | (3.26) | Loss narrowed | (2.45) | Loss narrowed |
| Net margin (%) | -219.8 | -638.8 | -533.3 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 27.19 | 16.56 | +64.2% | 14.91 | +82.4% |
| Other income | 0.00 | 4.40 | −100.0% | 0.19 | −100.0% |
| Total income | 27.19 | 20.96 | +29.7% | 15.10 | +80.1% |
| Profit before tax | (60.98) | (106.69) | Loss narrowed | (79.71) | Loss narrowed |
| Net profit for the period | (60.98) | (106.69) | Loss narrowed | (79.71) | Loss narrowed |
| EPS, basic (₹) | (1.88) | (3.29) | Loss narrowed | (2.46) | Loss narrowed |
| Net margin (%) | -224.3 | -644.3 | -534.6 |
Consolidated
- Filed with BSE
- 19 May 2025, 21:36 IST
- Board meeting
- 19 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 19 May 2025, 21:36 IST
- Board meeting
- 19 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE